CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL)
The Pharma Data
JUNE 18, 2021
Patients received 3 cycles of ibrutinib lead-in followed by 12 cycles of ibrutinib + venetoclax (Ibr 420 mg/day PO; Ven ramp up to 400 mg/day PO). NORTH CHICAGO, Ill. NORTH CHICAGO, Ill. months of follow up. This rate was higher than the 37% minimum meaningful rate study assumption (P<0.0001).
Let's personalize your content